Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma (NAMS) EBIT (2023 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed EBIT for 3 consecutive years, with $107.1 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 347.79% to $107.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$52.6 million through Dec 2025, up 70.17% year-over-year, with the annual reading at -$52.6 million for FY2025, 70.17% up from the prior year.
  • EBIT hit $107.1 million in Q4 2025 for NewAmsterdam Pharma, up from -$55.1 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $107.1 million in Q4 2025 to a low of -$68.9 million in Q1 2025.
  • Historically, EBIT has averaged -$34.3 million across 3 years, with a median of -$46.4 million in 2023.
  • Biggest YoY gain for EBIT was 347.79% in 2025; the steepest drop was 120.55% in 2025.
  • Year by year, EBIT stood at -$51.1 million in 2023, then increased by 15.36% to -$43.2 million in 2024, then surged by 347.79% to $107.1 million in 2025.
  • Business Quant data shows EBIT for NAMS at $107.1 million in Q4 2025, -$55.1 million in Q3 2025, and -$35.6 million in Q2 2025.